BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy

Nanoscale
Huijie ZhangJinghua Chen

Abstract

CpG oligodeoxynucleotides (CpG ODNs) possess strong immunostimulatory activity, which hold great promise in cancer immunotherapy. However, their therapeutic efficacy is largely limited due to nuclease degradation and poor cellular internalization. Efficiently delivering CpG ODNs into target cells is crucial to improve their therapeutic efficacy. Boron nitride nanospheres (BNNS) possess advantage as carriers for CpG ODNs. However, their poor aqueous dispersity and low CpG ODN loading capacity became a big obstacle for further applications. Herein, we develop amino group grafted, mesoporous silica (MS)-functionalized BNNS as novel nanovectors for CpG ODN delivery. Modification of BNNS with MS significantly improved the dispersity of BNNS and CpG ODN loading. BNNS@MS-NH2 exhibited no cytotoxicity and enhanced the delivery of CpG ODNs into macrophages. BNNS@MS-NH2/CpG ODN complexes triggered enhanced immunostimulation and induced higher amounts of cytokines. Most importantly, BNNS@MS-NH2/CpG ODN complexes induced bifurcated cytokines, which simultaneously simulated the secretion of IL-6, TNF-α and IFN-α. In contrast, CpG ODN and BNNS/CpG ODN complexes could not. The result of the Transwell plate assay suggested that BNNS@MS-NH2/CpG...Continue Reading

References

Apr 6, 1995·Nature·A M KriegD M Klinman
Dec 29, 2000·Nature·H HemmiS Akira
Apr 2, 2004·Nature Reviews. Immunology·Dennis M Klinman
May 19, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·George K MutwiriLorne A Babiuk
Jan 6, 2005·Journal of the American Chemical Society·Alberto BiancoCharalambos D Partidos
Jun 10, 2006·Nature Reviews. Drug Discovery·Arthur M Krieg
Jan 6, 2009·Journal of the American Chemical Society·Xing ChenCarolyn R Bertozzi
Nov 10, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Yanal M Murad, Timothy M Clay
Aug 7, 2010·Small·Juan L Vivero-EscotoVictor S-Y Lin
May 24, 2012·International Journal of Nanomedicine·Nobutaka Hanagata
Feb 3, 2016·Advanced Materials·Yu ZhangChunhai Fan
Feb 26, 2016·Nature Reviews. Cancer·Belinda S ParkerPaul J Hertzog
May 14, 2016·Chemical Society Reviews·Qunhong WengDmitri Golberg
Oct 25, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Huijie Zhang, Xiao-Dong Gao
Jan 7, 2017·Nature Communications·Xia LiDmitri Golberg
Feb 12, 2017·Materials Science & Engineering. C, Materials for Biological Applications·Huijie ZhangXiao-Dong Gao
May 6, 2017·Chemical Communications : Chem Comm·Wenshan LiKemin Wang
Jun 2, 2017·ACS Applied Materials & Interfaces·Yijiao QuBaoquan Ding
Oct 4, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bas D KosterTanja D de Gruijl
Oct 27, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J OvermanS Kopetz
Dec 15, 2017·Advanced Materials·Ashley V KrollLiangfang Zhang
Feb 15, 2018·International Journal of Nanomedicine·Shini FengHideki Nakanishi

❮ Previous
Next ❯

Citations

Mar 19, 2021·International Journal of Nanomedicine·Shini FengFuxue Chen
Jun 1, 2020·Medicine in Drug Discovery·Shurong ZhouGuizhi Zhu
Jan 19, 2021·ACS Biomaterials Science & Engineering·Congshan YuanXiguang Chen
Dec 4, 2019·Molecular Pharmaceutics·Fuping ShaoYe Yang
Nov 11, 2019·ACS Biomaterials Science & Engineering·Huijie ZhangJinghua Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
Confocal
Flow cytometry

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.